QuidelOrtho (NASDAQ:QDEL) Releases Quarterly Earnings Results, Beats Estimates By $0.13 EPS

QuidelOrtho (NASDAQ:QDEL) announced its quarterly earnings results on Tuesday. The company reported $0.31 earnings per share (EPS) for the quarter, topping the consensus estimate of $0.18 by $0.13, FiscalAI reports. The business had revenue of $618.90 million during the quarter, compared to the consensus estimate of $627.83 million. QuidelOrtho had a positive return on equity of 4.88% and a negative net margin of 39.20%. QuidelOrtho’s revenue was down 11.6% compared to the same quarter last year. During the same quarter in the prior year, the company posted $0.80 earnings per share.

Here are the key takeaways from QuidelOrtho’s conference call:

• China and respiratory weakness drove the decline: Q3 revenue fell 12% to $619 million, with China down 45% and Point of Care down 27% as respiratory revenue declined 39%. Management expects China to fall from about 8% of revenue in 2026 to 4%–5% in 2027 amid destocking, pricing pressure, and competition.
• Core businesses continued to grow outside China: Labs revenue rose 4% and immunohematology revenue rose 3%, supported by demand across key markets and the company’s installed base.
• A new restructuring program targets more than $80 million in annual savings in 2027, which management says should more than offset near-term China headwinds. The program will incur $30 million–$35 million in restructuring charges, with most of the cash outflow expected in Q4 2026.
• Guidance and leverage reflect continued pressure: The company narrowed 2026 revenue guidance to $2.52 billion–$2.54 billion and expects adjusted EBITDA of $540 million–$545 million and adjusted EPS of $0.65–$0.70. Free cash flow was approximately break-even in Q3, while net leverage rose to 4.5x from 4.3x in Q2.

QuidelOrtho Stock Performance

Shares of NASDAQ QDEL traded up $0.31 during midday trading on Wednesday, reaching $14.40. The company’s stock had a trading volume of 380,397 shares, compared to its average volume of 1,775,643. QuidelOrtho has a 12-month low of $9.92 and a 12-month high of $35.58. The firm has a 50 day moving average price of $12.74 and a 200-day moving average price of $16.27. The stock has a market capitalization of $987.68 million, a P/E ratio of -0.93 and a beta of 0.77. The company has a debt-to-equity ratio of 1.43, a current ratio of 1.39 and a quick ratio of 0.76.

Analysts Set New Price Targets

A number of equities analysts have issued reports on QDEL shares. Weiss Ratings reaffirmed a “sell (e+)” rating on shares of QuidelOrtho in a report on Thursday, October 15th. Zacks Research upgraded shares of QuidelOrtho from a “strong sell” rating to a “hold” rating in a research note on Friday, October 9th. Finally, Citigroup increased their target price on shares of QuidelOrtho from $13.00 to $18.00 and gave the company a “neutral” rating in a report on Wednesday, July 8th. Four investment analysts have rated the stock with a Hold rating and two have given a Sell rating to the company. Based on data from MarketBeat, the company currently has a consensus rating of “Reduce” and a consensus price target of $13.62.

Key Headlines Impacting QuidelOrtho

Here are the key news stories impacting QuidelOrtho this week:

• Positive Sentiment: Adjusted earnings were $0.31 per share, above the $0.18 consensus estimate. Zacks earnings report
• Positive Sentiment: The company announced a cost-transformation and restructuring program expected to generate more than $80 million in annual savings in 2027. QuidelOrtho third-quarter results
• Neutral Sentiment: QuidelOrtho cited growth in labs and immunohematology outside China as areas of underlying business strength, and narrowed its full-year 2026 guidance ranges. QuidelOrtho third-quarter results
• Negative Sentiment: Revenue was $619 million, below analysts’ roughly $628 million estimate and down 12% year over year. Earnings also fell from $0.80 per share a year earlier. The sales shortfall and continuing year-over-year declines likely overshadowed the EPS beat. Q3 sales report

About QuidelOrtho

QuidelOrtho Corporation (NASDAQ:QDEL) is a global in vitro diagnostics company formed through the combination of Quidel Corporation and Ortho Clinical Diagnostics, a transaction completed in 2022. The company develops, manufactures and markets diagnostic technologies used to detect disease, guide treatment decisions and support blood-transfusion safety.

Its portfolio includes rapid immunoassays, molecular testing systems, clinical chemistry and immunohematology products, as well as laboratory automation solutions.